The ShigETEC is a live attenuated combined vaccine for Shigella and ETEC strains with targeted genetic mutations. The oral vaccine was developed by Eveliqure Biotechnologies GmbH. The key features of the ShigETEC vaccine are: 1) Deletion of the serotype-determining LPS O-antigen, 2) Inactivation of the type III secretion system, 3) Inactivation of a putative enterotoxin, 4) Increased stability of the vaccine strain by transposition of an essential gene from the chromosome to the Shigella's invasion plasmid, 5) Expression of a tandem repeat of a fusion protein of LTB and an ST toxoid that induces neutralizing antibodies and thus protective immunity against both toxins of ETEC strains.